Since 2001’s discovery of microRNAs (miRNAs) in humans, progresses in genomics and transcriptomics have increased our comprehension of gene expression regulation. miRNAs are small, noncoding RNA molecules showing huge promise as clinical biomarkers and diagnostic tools for illness and disease, as significant changes in their expression occur in response to pathological states. However, considerable challenges remain today, since costly, complex sample preparations and RNA amplifications are not yet reliable enough for clinical decision making. In this context, two innovative EU SMEs, Optoi Microelectronics – with microelectronic knowhow and manufacturing skills – and DestiNA Genomics – with ‘error free’ chemical technology for microRNAs recognition – combined forces with three key academic research groups from the Universities of Trento (Italy), Granada (Spain) and Santa Caterina (Brazil). All the parties have combined their knowledge with respect to miRNA disease biomarkers with a particular focus on lung cancer, so as to develop a novel and reliable miRNA detection system for this disease. To this end, research collaborations will address the analysis of miRNAs specifically over-expressed in lung cancer, continuing experimental work already started in the past years, but with greater integration and focus. Existing close partnerships with healthcare institutions will be preserved and strengthened, ensuring multi-site and multi-ethnic sampling. In parallel, optimization and validation of a miRNA detection kit based on Optoi’s semiconductor optical detector will continue. The DestiNA patented technology for ‘error free’ specific nucleic acid recognition will be refined to reach the integration and result reliability required for use in clinical point of care testing. Recently, the Medical School of Hannover and the company GeneXplain have joined the consortium. The strong network created between the three SMEs and the four academic institutions will thus provide a unique scientific and technological environment to turn the research outputs into an innovative product for healthcare advance and progress.
Posibles nuevas herramientas de diagnóstico para diagnóstico precoz y medicina personalizada.
Paseo del Salón. Plaza del Humilladero, 10, 18005 Granada, Granada, España
Grupo de investigación “Fotoquímica y Fotobiología” (FQM-247). Departamento de Fisicoquímica.
Horizonte 2020. Programa MSCA-RISE
Importe: 445,500.00 €
Universidad de Granada; DestiNA Genómica S.L.; Optoelettrónica Italia; GeneXplain GmbH; Universidad de Trento; Universidad de Santa Catarina; Hospital Universitario de Hannover
La actividad propuesta tratará temas relacionados con la naturaleza de los ultrasonidos, su importancia en la ingeniería y cómo pueden ser utilizados para caracterizar los tejidos y aplicarse a la medicina.
Se presenta el proceso realizado para validar un instrumento de evaluación.